ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Glaxo To File Experimental Diabetes Drug Albiglutide In Early 2013

By Sten Stovall LONDON--GlaxoSmithKline PLC (GSK) aims to file its experimental once-weekly diabetes drug albiglutide for regulatory approval early next year following the read-out from a series of clinical trials. The British company said Wednesday that top-line data from eight late-stage Phase III clinical studies had now been received and, when taken together, support advancing albiglutide to regulatory submission. Albiglutide is an investigational biological form of human GLP-1 and isn't currently approved anywhere in the world. Human Genome Sciences (HGSI) discovered albiglutide and licensed it to Glaxo for late-stage testing. The drug is a form of GLP-1--a human protein that helps the body maintain normal blood-sugar levels. Glaxo's regulatory filings for albiglutide will be based on a Phase III clinical development program comprising eight individual studies, known as Harmony 1 to Harmony 8, involving some 5,000 patients. The program is investigating the efficacy, tolerability and safety, including cardiovascular safety, of albiglutide as mono- and add-on therapy, in patients with Type 2 diabetes. The latest read out came from Harmony 8, a 52-week study comparing albiglutide with Januvia, made by Merck & Co (MRK). Glaxo said Harmony 8 "is the first completed study of a GLP-1 agonist to assess efficacy and safety across the spectrum of renal impairment from mild to severe, and the third of eight Harmony Phase III studies to complete." It said albiglutide was generally well-tolerated. Results from the eight studies rule out excess cardiovascular risk, according to a threshold prespecified by the U.S. Food and Drug Administration. "Analyses of the data support progression to submission and will be presented to health authorities in the coming months," the company said. Shares in Glaxo closed up 0.8% at 1,465 pence. -Write to Sten Stovall at Sten.Stovall@DowJones.com

Stock News for Merck (MRK)
DateTimeHeadline
08/23/201603:03:00Deal for Medivation Is the Latest In a Line of Similar Acquisitions...
08/22/201612:52:00Pfizer's Medivation Deal Latest in Long Line of Similar Acquisitions
08/10/201616:58:47Statement of Changes in Beneficial Ownership (4)
08/09/201603:03:00Botox Maker Allergan's Revenue Climbs, but Loss More Than Doubles...
08/08/201617:05:00Results from Merck’s Phase 3 Study Evaluating ZEPATIER™ (elbasvir & g...
08/08/201616:41:16Quarterly Report (10-q)
08/08/201614:56:00Allergan Revenue Increases, Though Loss Widens--Update
08/08/201611:59:00MARKET SNAPSHOT: Stocks Retreat From Records As Health-care Stocks...
08/08/201610:20:00MARKET SNAPSHOT: Stocks Fight To Maintain Record-setting Pace...
08/08/201606:45:00REPEAT/FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Pa...
08/05/201619:30:00FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients wi...
08/05/201617:49:32Statement of Changes in Beneficial Ownership (4)
08/05/201612:58:00Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer...
08/05/201610:36:00Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer...
08/05/201610:15:00Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer...
08/05/201609:39:00Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer...
08/05/201609:20:00Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer...
08/05/201609:12:00Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer...
08/05/201608:00:00Merck Announces U.S. FDA Filing Acceptance of New Drug Application...
08/04/201614:30:37Statement of Changes in Beneficial Ownership (4)

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad